SciELO - Scientific Electronic Library Online

 
vol.36 número3Determinación de levodropropizina en gotas orales por cromatografía líquida de alta resoluciónUtilización de antiepilépticos en un hospital general de Ciudad de La Habana índice de autoresíndice de materiabúsqueda de artículos
Home Pagelista alfabética de revistas  

Servicios Personalizados

Revista

Articulo

Indicadores

  • No hay articulos citadosCitado por SciELO

Links relacionados

  • No hay articulos similaresSimilares en SciELO

Compartir


Revista Cubana de Farmacia

versión impresa ISSN 0034-7515versión On-line ISSN 1561-2988

Resumen

GARCIA FARINAS, Anaí; FARINAS REINOSO, Ana Teresa  y  GALVEZ, Ana María. Uso del meprobamato en el tratamiento de la hipertensión arterial: Consecuencias económicas. Rev Cubana Farm [online]. 2002, vol.36, n.3, pp.157-161. ISSN 0034-7515.

The hypertensive population taking meprobamate as part of the arterial hypertension treatment was characterized and the economic effect of this inadequate therapy for the individual and for the society was calculated. 27 patients over 15 that were treated with this drug were studied. 40.7 % of these patients referred to unappropriated therapeutic properties of this drug as hypotensive. The impossibility to have the drug influenced on the quality of life of the patients. 51.8 % felt uncontrolled when they could not take the drug. Every patient spent between $1.60 and $40.00 a month, depending on the way of acquisition. As a result of the research, it was concluded that the inadequate administration of meprobamate as a hypotensive agent brings about an unnecessary drug dependance that together with the increase of the production demand in the industrial setting, provoke the utilization of resources in its production and affect other options.

Palabras clave : MEPROBAMATE [therapeutic use]; HYPERTENSION [drug therapy]; COST OF ILLNESS; EXPENDITURES; DRUGS USE HABITS.

        · resumen en Español     · texto en Español     · Español ( pdf )

 

Creative Commons License Todo el contenido de esta revista, excepto dónde está identificado, está bajo una Licencia Creative Commons